RxDoctor Payments Data

Folashade Lester, MD

Family Medicine · Plano, TXNPI 1730279704

Payments from drug & device makers

$4,868in general payments, 2019–2025

Across 261 payments — averaging $18.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$843
  • AstraZeneca$835
  • AbbVie$538
  • Biohaven Pharmaceuticals, Inc.$237
  • Merck$219
  • Corium, LLC$206
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$4,862100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,868 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$39,573
Medicare patients
116
Services billed
496

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin21$27,452
OzempicSemaglutide13$21,359
JanuviaSitagliptin Phosphate12$17,903
Repatha SureclickEvolocumab15$17,845
FarxigaDapagliflozin Propanediol13$12,324
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid17$3,878
Rosuvastatin Calcium138$1,232
Clomipramine Hcl11$1,042
Albuterol Sulfate HfaAlbuterol Sulfate33$1,028
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide98$990
Atorvastatin Calcium109$803
Potassium Chloride23$795
Bupropion XlBupropion Hcl32$793
Levothyroxine Sodium109$728
Amlodipine Besylate134$720

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$82$27,45221 claims
Novo NordiskOzempic$843$21,35913 claims
MerckJanuvia$219$17,90312 claims
AstraZenecaFarxiga$835$12,32413 claims
AbbVieSynthroid$538$60211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →